<SEC-DOCUMENT>0001654954-19-002574.txt : 20190312
<SEC-HEADER>0001654954-19-002574.hdr.sgml : 20190312
<ACCEPTANCE-DATETIME>20190312083808
ACCESSION NUMBER:		0001654954-19-002574
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190312
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190312
DATE AS OF CHANGE:		20190312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52898
		FILM NUMBER:		19674025

	BUSINESS ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5
		BUSINESS PHONE:		514-426-6161

	MAIL ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sbfm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
U.S. SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
WASHINGTON, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 16px">
Form 8-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Current
Report Pursuant to Section 13 or 15(d) of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (Date of earliest event reported):</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
March 12, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of small business issuer as specified in its
charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Colorado</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
000-52898</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
20-5566275</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">of
incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission
File Number)</font></div>
</td>
<td style="vertical-align: top; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer ID No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
6500 Trans-Canada Highway</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
4th Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Pointe-Claire, Quebec, Canada H9R 0A5</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Address
of principal executive offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
(514) 426-6161</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Issuer&#x2019;s
Telephone Number)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;240.12b-2 of this chapter).&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company&#xA0;&#xA0;&#xA0;[X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; break-after: page; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 7.01 Regulation FD Disclosure</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
Our Press Release relating to the availability of our new
product,</font> Essential 9<font style="font-size: 70%; vertical-align: top">TM</font> on Amazon.ca is
attached as Exhibit 99.8 and is hereby incorporated as if set
forth.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 8.01 Other Events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 14, 2018, Health Canada issued NPN 80089663 through which
it authorized us to begin the manufacture and sale of our Essential
9<font style="font-size: 70%; vertical-align: top">TM</font>
product. Essential 9<font style="font-size: 70%; vertical-align: top">TM</font> is a dietary
supplement tablet that contains a balanced formula of the 9
essential amino acids that the human body cannot make. Our product
is now available for purchase on www.amazon.ca.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Essential
9<font style="font-size: 70%; vertical-align: top">TM</font> is a
dietary supplement tablet that contains a balanced formula of the 9
essential amino acids. <font style="color: #000000">Like vitamins,
Essential Amino Acids cannot be made by the human body and must be
obtained through diet. Deficiency in one or more of the 9 Essential
Amino Acids can lead to loss of muscle mass, fatigue, weight gain
and reduced ability to build muscle mass in athletes. Our Essential
9</font><font style="font-size: 70%; vertical-align: top; color: #000000">TM</font>
<font style="color: #000000">product provides all 9 Essential Amino
Acids in freeform and in the proportions recommended by Health
Canada.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">While
no assurances can be provided, we anticipate that Essential
9<font style="font-size: 70%; vertical-align: top">TM</font> will
soon be available on <font style="text-decoration: underline; color: #0000FF">www.Amazon.com</font><font style="text-decoration: underline; color: #0000FF">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 9.01 Financial Statements and Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(b)
Exhibits. The following exhibits are included in this
report:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">No.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Description</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px"><a href="sbfm_ex998.htm">99.8</a>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Press Release
Announcing Availability of Essential 9<font style="font-size: 70%; vertical-align: top">TM</font> on
Amazon.ca</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold">SUNSHINE BIOPHARMA,
INC.<br></font></font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Dated: March 12,
2019<br></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ Dr. Steve N
Slilaty<br></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<font style="font-size: 13px; font-family: Times New Roman">Dr.
Steve N Slilaty</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;"><font style="font-family: Times New Roman; font-size: 13px">Chief Executive
Officer</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<br>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>2
<FILENAME>sbfm_ex998.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 99.8</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="sunshinebio.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Immediate Release</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
March 12, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9&#x2122; IS NOW
AVAILABLE ON AMAZON.CA<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Montreal,
Quebec, Canada &#x2013; (ACCESSWIRE) &#x2013; Sunshine Biopharma,
Inc. (OTC Markets: &#x201C;SBFM&#x201D;) today announced that its
recently launched micronutrients supplement, Essential
9<font style="font-size: 70%; vertical-align: top">TM</font>, is
now available on <font style="text-decoration: underline; color: #0000FF">www.Amazon.ca</font>.
<a name="_Hlk3201096"><!--anchor--></a>On December
14, 2018, Health Canada issued NPN 80089663 through which it
authorized Sunshine Biopharma to manufacture and sell the Essential
9<font style="font-size: 70%; vertical-align: top">TM</font>
product. Essential 9<font style="font-size: 70%; vertical-align: top">TM</font> is a dietary
supplement tablet that contains a balanced formula of the 9
essential amino acids that the human body cannot make. Sunshine
Biopharma anticipates that Essential 9<font style="font-size: 70%; vertical-align: top">TM</font> will soon be
available on <font style="text-decoration: underline; color: #0000FF">www.Amazon.com</font>.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About Essential 9<font style="font-size: 70%; vertical-align: top">TM</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Essential Amino Acids are 9 out of the 20 amino acids required for
protein synthesis. Proteins are involved in all body functions
&#x2013; from the musculature and immune system to hormones and
neurotransmitters.</font> <font style="color: #000000">Like
vitamins, Essential Amino Acids cannot be made by the human body
and must be obtained through diet. Deficiency in one or more of the
9 Essential Amino Acids can lead to loss of muscle mass, fatigue,
weight gain and reduced ability to build muscle mass in athletes.
Sunshine Biopharma&#x2019;s Essential 9</font><font style="font-size: 70%; vertical-align: top; color: #000000">TM</font>
<font style="color: #000000">provides all 9 Essential Amino Acids
in freeform and in the proportions recommended by Health Canada.
Essential 9</font><font style="font-size: 70%; vertical-align: top; color: #000000">TM</font>
<font style="color: #000000">is suitable for everyone: vegans,
athletes, seniors, dieters.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Safe Harbor Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Additional Information:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Sunshine Biopharma, Inc.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Camille
Sebaaly, CFO</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Direct
Line: 514-814-0464</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-family: Times New Roman; font-size: 13px">
camille.sebaaly@sunshinebiopharma.com</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-family: Times New Roman; font-size: 13px">
www.sunshinebiopharma.com</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sunshinebio.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sunshinebio.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M2NHM/&GAV_,(M]5@/G-LB9LJ';T!(P35W4=>TS2;JVMK^Z2"6Y<)"'!P[$X
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MAHHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!.U4K*,&>YN/XI)-H)_NKQC\\U=J"U_U/\ P)O_
M $(TULR6KM%BBBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
